Phaseline

Companies › NEC OncoImmunity

NEC OncoImmunity: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NECVAX-NEO1
Personalized neoantigen-based T-cell vaccine using oral Ty21a vector with eukaryotic expre
–Phase 1Solid Tumors, Adult–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05354323NECVAX-NEO1Phase 1Solid Tumors, AdultOncologyDec 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.